Never a dull moment when it comes to Neuromodulati
Post# of 8574
(Total Views: 337)
Posted On: 07/13/2022 9:55:05 PM
Never a dull moment when it comes to Neuromodulation.
Regarding my earlier post, please jump to article below dated June 29th:
Industry News Briefs from the
International Neuromodulation Society
Industry News Feed
2022 News Briefs
International Neuromodulation Society
Company Announces Its Neurostimulation System Received FDA Breakthrough Device Designation
July 12, 2022 - Abbott announced it received FDA breakthrough device designation for investigation of its deep brain stimulation system in the treatment of treatment-resistant depression. (Source: Mass Device)
The FDA Permits Device Company to Start a Clinical Trial in Obstructive Sleep Apnea
July 11, 2022 - Nyxoah SA has received FDA approval for a clinical trial to evaluate their hypoglossal neurostimulator in adults with obstructive sleep apnea and complete concentric collapse of the soft palate. (Source: Street Insider)
Companies' Collaboration Aims to Add Artificial Intelligence Analysis to Chronic Pain Therapy Data
July 8, 2022 - Boston Scientific and IBM Research are collating data from spinal cord stimulation studies in a bid to objectively analyze or monitor patients' chronic pain experiences. (Source: Yahoo! Entertainment)
Company Raises $110 Million in Series D Financing, Plans to Trade Publicly, and Enters a Collaboration Regarding Potential Neuromodulation Treatment in Heart Patients
July 5, 2022 - Orchestra Biomed announced a strategic collaboration with Medtronic and a plan to become a publicly traded company, in addition to finalizing a Series D round of financing for $110 million. In the strategic collaboration, the company will further develop its BackBeat Cardiac Neuromodulation Therapy as a potential treatment for hypertension in patients indicated for a cardiac pacemaker. In the plans to trade publicly on Nasdaq, the company said it will enter a definitive business combination agreement with the special purpose acquisition company HSAC2. The deal would provide a minimum of $70 million at closing, and potentially up to $160 million if no HSAC shareholders redeem shares. (Source: Mass Device)
Company Points to Preclinical Evidence for Investigational Functional Electrical Stimulation Technique
June 30, 2022 - Onward Medical N.V. announced that publication of a study in non-human primates shows potential for the company's implantable investigational neurostimulation system to help restore hand and arm motion in people with spinal cord injury. (Source: Business Wire)
****************************************************
New Reimbursement Codes Anticipated in U.S. for Noninvasive Neurostimulation Method for Chronic Pain
June 29, 2022 - NeuraLace Medical announced new reimbursement codes will come into effect in January 2023 in the U.S. for its noninvasive neurostimulation device for chronic neuropathic pain. (Source: PR Newswire)
*****************************************************
Regarding my earlier post, please jump to article below dated June 29th:
Industry News Briefs from the
International Neuromodulation Society
Industry News Feed
2022 News Briefs
International Neuromodulation Society
Company Announces Its Neurostimulation System Received FDA Breakthrough Device Designation
July 12, 2022 - Abbott announced it received FDA breakthrough device designation for investigation of its deep brain stimulation system in the treatment of treatment-resistant depression. (Source: Mass Device)
The FDA Permits Device Company to Start a Clinical Trial in Obstructive Sleep Apnea
July 11, 2022 - Nyxoah SA has received FDA approval for a clinical trial to evaluate their hypoglossal neurostimulator in adults with obstructive sleep apnea and complete concentric collapse of the soft palate. (Source: Street Insider)
Companies' Collaboration Aims to Add Artificial Intelligence Analysis to Chronic Pain Therapy Data
July 8, 2022 - Boston Scientific and IBM Research are collating data from spinal cord stimulation studies in a bid to objectively analyze or monitor patients' chronic pain experiences. (Source: Yahoo! Entertainment)
Company Raises $110 Million in Series D Financing, Plans to Trade Publicly, and Enters a Collaboration Regarding Potential Neuromodulation Treatment in Heart Patients
July 5, 2022 - Orchestra Biomed announced a strategic collaboration with Medtronic and a plan to become a publicly traded company, in addition to finalizing a Series D round of financing for $110 million. In the strategic collaboration, the company will further develop its BackBeat Cardiac Neuromodulation Therapy as a potential treatment for hypertension in patients indicated for a cardiac pacemaker. In the plans to trade publicly on Nasdaq, the company said it will enter a definitive business combination agreement with the special purpose acquisition company HSAC2. The deal would provide a minimum of $70 million at closing, and potentially up to $160 million if no HSAC shareholders redeem shares. (Source: Mass Device)
Company Points to Preclinical Evidence for Investigational Functional Electrical Stimulation Technique
June 30, 2022 - Onward Medical N.V. announced that publication of a study in non-human primates shows potential for the company's implantable investigational neurostimulation system to help restore hand and arm motion in people with spinal cord injury. (Source: Business Wire)
****************************************************
New Reimbursement Codes Anticipated in U.S. for Noninvasive Neurostimulation Method for Chronic Pain
June 29, 2022 - NeuraLace Medical announced new reimbursement codes will come into effect in January 2023 in the U.S. for its noninvasive neurostimulation device for chronic neuropathic pain. (Source: PR Newswire)
*****************************************************
(0)
(0)